S
3.95
-0.03 (-0.75%)
| Penutupan Terdahulu | 3.98 |
| Buka | 3.95 |
| Jumlah Dagangan | 863,508 |
| Purata Dagangan (3B) | 1,557,640 |
| Modal Pasaran | 795,146,112 |
| Harga / Buku (P/B) | 14.01 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 14 Nov 2025 |
| EPS Cair (TTM) | -0.490 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 20.08% |
| Nisbah Semasa (MRQ) | 14.91 |
| Aliran Tunai Operasi (OCF TTM) | -95.63 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -56.02 M |
| Pulangan Atas Aset (ROA TTM) | -38.97% |
| Pulangan Atas Ekuiti (ROE TTM) | -75.77% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Savara, Inc. | Menaik | Menaik |
AISkor Stockmoo
1.7
| Konsensus Penganalisis | 5.0 |
| Aktiviti Orang Dalam | -2.5 |
| Volatiliti Harga | -0.5 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 4.0 |
| Purata | 1.70 |
|
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 5.38% |
| % Dimiliki oleh Institusi | 98.53% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 11.00 (JMP Securities, 178.48%) | Beli |
| 11.00 (Guggenheim, 178.48%) | Beli | |
| Median | 10.50 (165.82%) | |
| Rendah | 9.00 (Oppenheimer, 127.85%) | Beli |
| Purata | 10.25 (159.49%) | |
| Jumlah | 4 Beli | |
| Harga Purata @ Panggilan | 4.13 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Oppenheimer | 14 Nov 2025 | 9.00 (127.85%) | Beli | 4.30 |
| 08 Sep 2025 | 8.00 (102.53%) | Beli | 3.85 | |
| Citizens | 13 Nov 2025 | 10.00 (153.16%) | Beli | 4.26 |
| JMP Securities | 23 Oct 2025 | 11.00 (178.48%) | Beli | 4.12 |
| Guggenheim | 09 Sep 2025 | 11.00 (178.48%) | Beli | 3.82 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| ELAM NEVAN C | - | 5.81 | -1,473 | -8,558 |
| WASFI YASMINE | - | 6.31 | -21,992 | -138,660 |
| Jumlah Keseluruhan Kuantiti Bersih | -23,465 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -147,218 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 6.06 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| WASFI YASMINE | Pegawai | 04 Dec 2025 | Dibuang (-) | 21,992 | 6.31 | 138,660 |
| ELAM NEVAN C | Pengarah | 02 Dec 2025 | Dibuang (-) | 1,473 | 5.81 | 8,558 |
| ELAM NEVAN C | Pengarah | 02 Dec 2025 | Pelaksanaan pilihan | 5,860 | - | - |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |